Abstract. Poly(ADP-ribose) polymerase (PARP) is a family of nuclear proteins which regulate a number of cell functions, such as DNA repair, transcription, remodelling of chromatin structure, cell division and cell death. We and others have recently demonstrated that down-regulation of cellular PARP activity, using pharmacological inhibitors, impairs a number of endothelial functions and angiogenesis. In the present study, we investigated the potential mechanisms underlying the antiangiogenic effect exerted by the potent PARP inhibitor GPI 15427, analyzing gene expression in human endothelial cells shortly after treatment with this compound. Analysis of gene and protein expression indicated that a 2-h exposure of human endothelial cells to GPI 15427 induced a rapid decrease of syndecan-4 (SDC-4), a transmembrane protein involved in modulation of cell signalling during angiogenesis that plays a role in endothelial cell migration and adhesion. Moreover, treatment with the PARP inhibitor induced a reduction of a helix-loop-helix transcription factor, the inhibitor of DNA binding-1 (Id-1), also implicated in the control of endothelial functions. We suggest that the inhibitory effect exerted by GPI 15427 on the angiogenic process is likely due to the reduced activity of specific transcription factors, such as Oct-1 and CREB that contribute to the regulation of SDC-4 and Id-1 expression, respectively. In conclusion, these results strongly suggest that PARP activity is capable of modulating molecules required for endothelial cell migration, adhesion, proliferation or differentiation during the angiogenic process.
Introduction
Poly(ADP-ribose) polymerase (PARP) is a family of eukaryotic nuclear proteins which plays a key role in regulating DNA repair, transcription, chromatin function, cell division and cell death (1) . PARPs synthesize polymers of ADP-ribose using NAD + as a substrate and catalyse the attachment of poly(ADP-ribose) to acceptor proteins modifying their function. This post-translational modification is transient due to the prompt degradation of the polymers by poly(ADPribose) glycohydrolase. Among the PARP family members, PARP-1 is responsible for most of the cellular poly(ADPribosyl)ating activity and its primary targets include PARP-1 itself, histones and a variety of transcription factors. So far, only PARP-1 and PARP-2 are known to be activated by DNA damage, acting as sensor of genotoxic damage and co-ordinating repair (1) . However, PARP-2 is less active than PARP-1 in the response to DNA damage and unique PARP-2 functions in various differentiation processes have been recently identified (2) .
PARP-1 and -2 are involved in the base excision repair (3), which corrects DNA base lesions including N-methylpurines induced by methylating agents and oxidized bases or single strand breaks generated by ionizing radiations (4) . Moreover, PARP-1 modulates the repair of double-strand breaks through its interaction with components of the non-homologous end joining (5) . In its poly(ADP-ribos)ylated form PARP-1 counteracts the action of topoisomerase I poisons facilitating resealing of DNA strand (6) . Recently, it has been demonstrated that PARP-1 may play a role also in the nucleotide excision repair pathway (7) . Thus, PARP inhibitors have been exploited in cancer treatment to increase the efficacy of chemotherapeutic agents such as temozolomide, dacarbazine, carboplatin, irinotecan, topotecan or of radiotherapy, and are currently under evaluation in phase I and II clinical trials for the treatment of refractory solid and hematological tumors (4, www.clinicaltrials.gov). PARP inhibitors are also investigated as single agents for the therapy of ovarian or breast cancer carrying mutations of breast cancer associated gene 1 and 2 (BRCA-1 and BRCA-2) which are involved in the homologous INTERNATIONAL JOURNAL OF ONCOLOGY 34: 861-872, 2009 861
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recombination repair machinery (8, 9 , www.clinicaltrials. gov). In addition to DNA repair mechanisms, targeting PARP-1 has been shown to suppress angiogenesis, which is an essential requirement for the growth of tumours. We recently demonstrated a direct involvement of PARP-1 function in angiogenesis as indicated by the reduction of blood vessel neo-formation in response to angiogenic stimuli observed in PARP-1 KO mice (10) . Similar results were obtained in animals treated with the potent PARP inhibitor GPI 15427 (10) . The observed anti-angiogenic effect of GPI 15427 is associated with a decrease of endothelial cell migration in response to angiogenic factors, such as the vascular endothelial growth factor (VEGF) or the placenta growth factor, and cannot be directly related to increased DNA damage, since it is observed at drug concentrations that do not affect the viability and the proliferative potential of endothelial cells. Similar anti-angiogenic effects were obtained also with other PARP inhibitors (11) (12) (13) . Notably, abrogation of PARP-1 expression by stable gene silencing reduced the aggressiveness of melanoma and this effect was associated with a decreased vasculature formation within the tumour (14) . Altogether, these data strongly suggest that PARP inhibitors may also exert antitumor activity through a reduction of tumour-associated neo-angiogenesis, independently on their effect on DNA repair.
In the present study, we demonstrate that a short exposure of human endothelial cells to the PARP inhibitor GPI 15427 induces a rapid decrease of the expression of syndecan-4 (SDC-4), a transmembrane protein involved in modulating cell signalling during angiogenesis, and a later reduction of the expression of inhibitor of DNA binding-1 (Id-1), a helixloop-helix transcription factor which regulates endothelial functions.
Materials and methods
Cell culture and treatment with PARP inhibitor. The immortalized human endothelial cell line HUV-ST was generated as previously described (15) . Cells were maintained in culture in endothelial growth factor medium (EGM-2; Clonetics, BioWhittaker Inc., Walkersville, MD, USA) supplemented with 0.4 mg/ml geneticin and 5 μg/ml puromycin.
For PARP inhibition in endothelial cells, the recently developed compound GPI 15427 [10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2-diaza-benzo [de] anthracen-3-one, Eisai, Baltimore, MD, USA] was used (16) . The PARP inhibitor stock solution (1 mM) was prepared by dissolving GPI 15427 in 70 mM PBS without potassium.
PARP activity assay. To measure total cellular PARP activity, HUV-ST cells (5x10 6 ) were lysed in 0.5 ml of a buffer containing 0.1% Triton X, 50 mM Tris-HCl pH 8.0, 0.6 mM EDTA, 14 mM ß-mercaptoethanol, 10 mM MgCl 2 and protease inhibitors. Proteins (25 μg) were incubated with 2 μCi 32 P-NAD + (GE Healthcare, Milan, Italy), 10 μM NAD + , 50 mM Tris-HCl, 10 mM MgCl 2 , 14 mM ß-mercaptoethanol, 10 μg nuclease-treated salmon testes DNA. PARP activity was expressed as fmol of 32 P-NAD + /μg of protein (16) . For the analysis of the influence of GPI 15427 on cellular PARP, intact HUV-ST cells (5x10 5 ) were treated with the inhibitor and permeabilized with digitonin (0.1 mg/ml) in the presence of 0.25 μCi 3 H-NAD + (PerkinElmer, Milan, Italy) (17) .
Microarray analysis of gene expression
Gene expression profiling. Total cellular RNA was isolated from endothelial cells using RNeasy kits (Qiagen, Germantown, MD, USA). Preparation of labeled cRNA and hybridization (GeneChip Human Genome U133A array, Affymetrix Inc., High Wycombe, UK) was performed according to the Affymetrix GeneChip expression analysis manual. Data analysis. Affymetrix GeneChip scanning was analyzed by a customized R language-based script (see www.r-project.org) which utilizes the Bioconductor packages (see www.bioconductor.org) for quality control analysis, data normalization, hierarchical cluster and identification of differentially expressed transcripts. Specifically, the 'gcrma package' was used for chip normalization and background correction; the 'vsn package' provided calibration and transformation of the probe intensities. The genefilter package was used to separate genes with high variance according to the interquartile range method.
Prediction analysis. Prediction analysis of microarrays (PAM) is a statistical technique for class prediction utilizing gene expression data using shrunken centroids. The method of nearest shrunken centroids identifies subsets of genes that best characterize each class (18) . In order to test the internal consistency and to explore the relationship among untreated or GPI 15427-treated cell samples and underlying features of gene expression the unsupervised cluster analysis was followed by PAM R supervised class prediction package.
Differentially expressed genes. To identify genes differentially expressed in GPI 15427-treated and untreated cell samples, we used a significant analysis of microarrays (SAM) test, which uses permutation to identify significant differences between different groups. Analysis was performed using the R package 'samr' which was applied in order to adjust P-values using a false discovery rate to identify genes that were significantly different between groups (19) .
The lists of genes modulated by treatment with GPI 15427 that are shown in the Results section correspond to the genes that resulted to be up-or down-modulated in both PAM and SAM analysis.
Gene function analysis. Regulated biological processes and molecular functions were identified by the GEPAS web-based application according to the Gene Ontology (http://www. geneontology.org) Consortium classification (20) .
Western blot analysis. Time-course experiments of specific protein expression were performed in semi-confluent cultures of HUV-ST cells, growing in 6-well plates. Cells were treated with 2 μM GPI 15427 for different periods of time; wells were, then, washed with PBS and cell lysates were prepared using a lysis buffer (150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 50 mM Tris-HCl pH 8.0) containing phosphatase (PhoSTOP, Roche Diagnostics, Mannheim, Germany) and protease (Complete Mini, EDTA-free, Roche) inhibitors. Samples were run in a 10% SDS-polyacrylamide gel and proteins were then transferred to supported nitrocellulose membranes (Hybond-C; GE Healthcare). Membranes were blocked in blocking solution Cruz Biotechnology (Santa Cruz, CA, USA); the monoclonal antibody anti-phospho-CREB/ATF-1 (1B6, diluted 1:1000) was purchased from Cell Signaling (Beverly, MA, USA). After washing with TBST buffer (0.1% Tween-20, 0.9% NaCl, 20 mM Tris-HCl, pH 7.4), membranes were incubated for 1 h at room temperature with the appropriate horseradishperoxidase conjugated secondary antibody (anti-rabbit or antimouse Ig from GE Healthcare, diluted 1:5000 in blocking solution). Membranes were then washed with TBST buffer and detection was carried out using the ECL Western blot detection reagents and Hyperfilm, both from GE Healthcare. Densitometric analysis was performed using a GS710 densitometer from Bio-Rad Laboratories (Hercules, CA, USA).
NF-κB and Oct-1 activation assays. Time-course experiments of transcription factors activity were performed in semiconfluent cultures of HUV-ST cells, growing in 6-well plates. Cells were treated with 2 μM GPI 15427 for different periods of time and then lysed to prepare nuclear extracts. Nuclear proteins were prepared using the Active motif nuclear extract kit (Active Motif Europe, Rixensart, Belgium) according to the manufacturer's instructions. Activation of the NF-κB p65 subunit in 10 μg of HUV-ST nuclear extracts was determined using an NF-κB p65 Enzyme-linked immunosorbent assay (ELISA)-based transcription factor assay kit (TransAM assay) (Active Motif Europe), according to the manufacturer's protocol. This kit contains a 96-well plate with immobilized oligonucleotides encoding an NF-κB consensus site (5'-GGGACTTTCC-3'). The active form of this transcription factor specifically binds to this oligonucleotide. The NF-κB detecting antibody recognizes an epitope on p65 that is accessible only when this polypeptide is activated and bound to its target DNA. A horseradish peroxidase-conjugated secondary antibody provides a sensitive colorimetric readout that is quantified by a Bio-Rad microplate reader 680 at 450 nm with a reference wavelength of 655 nm. The positive control Jurkat nuclear extract, provided within the kit, was used to assess assay specificity.
Oct-1 activity was assayed using a modified Oct-4 TransAM kit from Active Motif Europe. In brief, the 96-well plate with immobilized oligonucleotides encoding the octamer binding transcription factor family consensus sequence (5'-ATGCAAAT-3') was utilized to capture the activated Oct-1 protein present in the HUV-ST nuclear extracts (10 μg). Then, the assay was performed according to the manufacturer's instructions using an anti-Oct-1 rabbit polyclonal antibody from Santa Cruz (C-21) diluted 1:1000. A nuclear extract from P19 cells, provided with the kit, was used as positive control.
Results

Analysis of differential gene expression in untreated or GPI 15427-treated HUV-ST cells. HUV-ST cells were initially
analyzed for PARP activity, measured in cell extracts in the presence of nuclease-treated salmon testes DNA and 32 P-NAD + . The results indicated that total PARP activity of HUV-ST cells was 853±178 fmol/μg of protein. We then tested the ability of GPI 15427 to inhibit PARP activity of intact endothelial cells by exposure of HUV-ST cells for 1 h to graded concentrations of GPI 15427 (0.1-2 μM), followed by permeabilization with digitonin in the presence of 3 H-NAD + . The results indicated that GPI 15427 easily penetrated into the cells and inhibited PARP activity with an IC 50 of 237±27 nM.
To investigate the early molecular changes after exposure of endothelial cells with GPI 15427, HUV-ST cells were treated for 2 h with 2 μM GPI 15427, a concentration that completely inhibits PARP activity and angiogenesis and that does not affect the growth and clonogenic survival of endothelial cells (10) . Total RNA was extracted from untreated (n=2) or drug-treated cultures (n=2) and gene expression was evaluated by microarray analysis. The identification of the differentially expressed genes showed that most of these genes were down-regulated by drug treatment (Tables I and II) . The genes demonstrating early modulated expression mainly Table I . Up-modulated genes after GPI 15427 treatment of endothelial cells. 
The list corresponds to the genes that resulted to be modulated in both PAM and SAM analysis.
b Score and fold change parameters were obtained by SAM analysis. Table II . Down-modulated genes after GPI 15427 treatment of endothelial cells. Table II . Continued. (Table III) . Only five of the down-modulated genes resulted to be involved in the angiogenic process: SDC-4, Id-1 and Id-3, tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) and nuclear factor of activated T-cells C3 (NFATC3) (Tables III and IV) . The protein inhibitor of activated STAT3 (PIAS3) was the only up-regulated gene involved in angiogenesis (Table III  and IV) .
Effect of GPI 15427 on SDC-4 and Id-1 expression.
The influence of treatment with GPI 15427 on SDC-4 and Id-1 expression in endothelial cells was further studied at the protein level by Western blot analysis (Fig. 1) . The results indicated that SDC-4 protein was strongly reduced (61 to 67% inhibition) in treated cells at short incubation times after drug exposure (2 and 6 h). At later time points, SDC-4 expression was up-regulated during the culture both in untreated or GPI 15427-treated endothelial cells. On the other Table II . Continued. 
-----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
a The list corresponds to the genes that resulted to be modulated in both PAM and SAM analysis. b Score and fold change parameters were obtained by SAM analysis.
hand, Id-1 protein expression started to be down-modulated only 6 to 24 h after treatment, with a 55% reduction in treated cells with respect to the untreated control at 30 h. The decrease of Id-1 protein expression occurred later with respect to that of the corresponding mRNA transcription which, instead, was detected 2 h after treatment with the PARP inhibitor. Experiments performed to analyze basal expression of Id-1 in HUV-ST cells indicated that this protein was absent in the cell extracts prepared from cultures grown in medium lacking growth factor supplements (data not shown).
Effect of GPI 15427 on transcription factor activity.
Gene functional analysis showed that the majority of modulated genes, including most of those involved in angiogenesis, are under the control of the transcription factor NF-κB, which is known to be regulated by PARP-1 (Table V) . Other transcription factors known to be regulated by PARP-1 are indicated in Table V . Among them, Oct-1 regulates 13% of the genes down-modulated by GPI 15427 treatment (including SDC-4), while AP-1 modulates 6.2% of the genes (but none of them related to angiogenesis). Only one gene, affected by Table III . Functional analysis of genes modulated after GPI 15427 treatment of endothelial cells. 
-----------------------------------------------------------------------------------------------------Biological process a Genes Percentage b -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
a Regulated biological processes were identified by the GEPAS web-based application according to the Gene Ontology Consortium classification.
b The values indicate the percentage of genes that have been assigned to each biological process among the total number of genes modulated by treatment of endothelial cells with GPI 15427. Table IV . Genes known to be involved in the angiogenic process that are modulated by treatment of endothelial cells with GPI 15427. 
----------------------------------------------------------------------------------------------------
a Score and fold change parameters were those obtained by SAM analysis.
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treatment with the PARP inhibitor, but not related to angiogenesis, is under the control of HIF-1. Interestingly, the members of the activating transcription factor family c-AMP response element binding protein (CREB)/ATF-1 and ATF-3 regulate the transcription of Id-1 (Table V) . The activity and/or expression of transcription factors that might be involved in the effect of GPI 15427 on the angiogenic capabilities of human endothelial cells were tested. The results indicated that in the endothelial cells used for the present study the NF-κB activity was very low and was not modulated by the PARP inhibitor ( Fig. 2A ). In the conditions tested, Oct-1 activity resulted to be only slightly, but significantly, downmodulated (up to 16%) by treatment with the inhibitor for 2 or 6 h (Fig. 2B) . Oct-1 protein is abundantly produced in HUV-ST cells, but its expression was not substantially modulated by GPI 15427 treatment (data not shown), suggesting that PARP-1 could directly modulate Oct-1 activity.
Analysis of CREB/ATF-1 levels and phosphorylation showed that both proteins were modulated during the period of culture analyzed, being barely detectable few hours after the beginning of culture and up-regulated at later time points. In the case of ATF-1, protein and phosphorylation levels were almost unaffected by the drug treatment (Fig. 3) . On the other hand, up-regulation of CREB expression was blocked by the PARP inhibitor and this effect was paralleled by a reduced phosphorylation of the protein. In regard to ATF-3, no changes in the level of protein expression were observed and a modest decrease of phosphorylation of this transcription factor was detected in the first 2 h (data not shown). 
Discussion
Following our recent publication on the role of PARP-1 in angiogenesis and on the impairment of endothelial functions mediated by PARP inhibition with GPI 15427 (10), we investigated the early molecular mechanisms involved in this effect analyzing the modulation of gene expression in endothelial cells treated with non-toxic concentrations of the PARP inhibitor. In the present study we demonstrate, for the first time, that SDC-4 and Id-1 proteins, which are both involved in angiogenesis, are down-regulated by GPI 15427 treatment.
Treatment of endothelial cells with the PARP inhibitor for 2 h provoked a prompt decrease of SDC-4 both at the transcript and protein level. SDC-4 is the most ubiquitously expressed member of a transmembrane heparin sulfate proteoglycans family that binds to and can be activated by insoluble ligands, such as extracellular matrix molecules, and soluble ligands, including growth factors (21) . Moreover, SDC-4 is activated by angiogenic factors and is involved in endothelial cell adhesion and migration (22, 23) . The effect of the treatment with the PARP inhibitor on SDC-4 expression in endothelial cells was transient, since 24 h after treatment the decrease of this protein was no longer detectable. Therefore, it is possible to hypothesize that SDC-4 protein might be required in the initial steps of the angiogenesis process, such as the triggering of endothelial cell migration from the pre-existing vessel, that is compatible with the known role of this protein in endothelial cell adhesion and migration (22, 23) .
The Id-1 protein was down-regulated by GPI 15427 at a later time point with respect to SDC-4. Id-1 is a member of the helix-loop-helix family of proteins that does not contain DNA binding sequences but prevents transcription factors from binding to DNA by direct physical interaction (24) . Id-1 plays a key role in regulating angiogenesis, including that associated with tumor development (25) . The expression of this protein can be induced in endothelial cells by VEGF and TGF‚ and its overexpression enhances I-CAM-1 and Eselectin expression, and provokes transmigration, matrix metalloproteinase production and tube formation (26) . Knockdown of Id-1 in endothelial cells abolished proliferation and angiogenic processes induced by VEGF (26) . Induction of the Id-1 protein by VEGF supports the hypothesis that the previously observed effects of GPI 15427 on VEGF-induced angiogenic processes (10) might indeed involve this protein.
A short exposure of endothelial cells to the PARP inhibitor resulted in transcription down-regulation of a limited number of genes known to play a role in angiogenesis. While SDC-4 and Id-1 were found to be the mostly affected genes, the other genes found to be inhibited were TNTRSF12A, a member of the TNF receptor family which interacts with TNF-like weak inducer of apoptosis (TWEAK) (27) , Id-3, another member of the helix-loop-helix family of proteins (25, 26) and NFATC3, a transcription factor belonging to a protein family controlled by calcineurin which regulates vascular development during angiogenesis (28) . Among the up-regulated genes, PIAS3 was the most significantly up-regulated. PIAS3 is a negative Table V . Genes modulated after GPI 15427 treatment of endothelial cells that are under the control of specific transcription factors regulated by PARP-1. 
a Transcription factors were identified by the GEPAS web-based application.
b The values indicate the percentage of genes, whose expression is regulated by each transcription factor with respect to the total number of genes modulated by GPI 15427 treatment of endothelial cells.
regulator of STAT3, a transcription factor involved in VEGF expression (29, 30) . However, in HUV-ST cells or in HUVEC the levels of VEGF released by the cells was extremely low and was not modulated by GPI 15427 treatment (10) .
Microarray analysis revealed a prevalent down-modulation of gene expression, the highest percentage of which is involved in regulation of gene transcription. It is well known that PARP-1 regulates transcription by at least two different mechanisms: modulating chromatin structure and acting as part of gene-specific enhancer/promoter-binding complexes (31) . This activity is accomplished by PARP-1 through a direct protein-protein interaction or through covalent poly(ADPribosyl)ation of the target molecule (32) . For instance, poly(ADP-ribosyl)ation of histones loosens chromatin and renders genes accessible to the transcriptional machinery. Moreover, non-covalent interaction of histones with poly (ADP-ribose), as free polymer or attached to proteins, may also allow release of histones from nucleosome rendering DNA accessible for transcription (32) (33) (34) . Even though in cells not subjected to DNA damage the average length of ADP-ribose polymers is shorter than in cells exposed to genotoxic injury, ADP-ribose polymers may still participate to the regulation of several functions also in intact cells. In addition, PARP-1 interacts with a number of transcription factors such as NF-κB, p53, Oct-1, B-MYB, AP-1, HIF-1, acting as transcriptional co-regulator (32) (33) (34) (35) (36) (37) . It is likely that the reduction of gene transcription induced by GPI 15427 might be the result of a decrease of cellular ADP-ribose polymers content rather than of compromised protein interactions with PARP-1. In fact, similarly to the other PARP inhibitors presently available, GPI 15427 targets the NAD + binding domain of the enzyme hampering the use of NAD + as substrate for the synthesis of ADP-ribose polymers (16) .
Gene functional analysis, performed according to the Gene Ontology Consortium classification, showed that about 28% of the genes (including Id-3, NFATC3, SDC-4 and PIAS3 which are involved in angiogenesis) modulated by GPI 15427 treatment of endothelial cells were under the control of NF-κB. Even though modulation of NF-κB by PARP-1 presumably requires direct protein-protein interaction, it has been shown that NF-κB is capable of binding poly(ADPribose), indicating that its activity may be regulated also by non-covalent interaction with the polymer (38) . Nevertheless, our results showed that in the endothelial cell model used NF-κB activity was barely detectable and was not modulated by treatment with the PARP inhibitor GPI 15427. Also HIF-1· was not found to be modulated by GPI 15427 in this model of endothelial cells (10) . Gene functional analysis showed that the transcription of 13% of down-regulated genes (including SDC-4) is controlled by the octamer trans-acting factor Oct-1, a transcription regulator capable of interacting with PARP-1, which stabilizes its binding to the DNA octamer motif (39) . This transcription factor was expressed by HUV-ST cells and its activity was slightly down-modulated by GPI 15427 in the assay used. Nevertheless, it cannot be excluded that the druginduced reduction of Oct-1 activity might be underestimated. In fact, it is likely that the physical interaction between Oct-1 and PARP-1 might not be fully maintained during the preparation of the nuclear extracts or during the in vitro activity assay.
PARP-1 has also been involved in the modulation of the ATF family of transcription factors, favoring phosphorylation of these proteins (40) . Functional analysis of genes modulated by GPI 15427 in endothelial cells indicated that members of the ATF protein family (ATF-1, CREB and ATF-3) regulate Ids gene expression. In particular, it has been shown in normal human keratinocytes that Ids transcription can be modulated through cis-acting elements in the distal portion of the promoter, including a CREB-binding site (41) . Therefore, it is possible that the strong down-modulation of activated CREB protein after 6 h of treatment would contribute to the reduction in Id-1 protein expression. The delayed decrease of Id-1 protein with respect to the prompt reduction of mRNA expression might depend on the half-life of the previously synthesized protein. As described by Ling and colleagues, the half-life of Id-1 protein is quite variable depending on cell type (42) . We observed that the increased stability of the protein appears to be a characteristic of endothelial cells maintained in medium with a mix of growth factors (bFGF, VEGF, EGF and IGF-1) (data not shown), some of which are known to sustain Id-1 expression (26) . Finally, the modest decrease of ATF-3 phosphorylation detected 2 h after treatment is unlikely to account for the reduction of Id-1 transcript since ATF-3 has been found to be a negative regulator of this protein (43) . Therefore, the initial inhibition of Id-1 transcript during the first 2 h of treatment with the PARP inhibitor might be due to the effect of the drug on other still undefined molecular mechanisms.
Previous studies have analyzed the effects of PARP-1 deficiency on gene expression at the genome wide-level, using murine PARP-1 -/-embryonic stem cell lines and cells of different tissue origin (37, 44, 45) or cells derived from PARP-1 +/+ mice treated with a PARP inhibitor (37) . The lack of PARP-1 expression was associated with both downregulation and up-regulation of genes involved in a variety of processes such as metabolism, signal transduction, cell cycle control and transcription, which varied depending on the cell system investigated (44) . In skin-derived cells obtained from P-1 -/-mice or from PARP-1 +/+ mice treated with the PARP inhibitor 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ), differences were found in genes involved in carcinogenesis and inflammation with respect to controls (37) . In regard to endothelial cells, gene expression profiles in response to TNF-· treatment were investigated in cells derived from the heart vasculature of PARP-1 -/-mice and the absence of PARP-1 was found to hamper the expression of genes up-regulated during the inflammatory process (45) . However, since no studies have been performed to date on human endothelial cells, it is difficult to make comparisons between our results and the previously published studies, due to the differences in the species, tissue origin and stimuli used.
In conclusion, treatment of human endothelial cells with the potent PARP inhibitor GPI 15427 induced a strong downmodulation of at least two gene products that play an important role in endothelial functions: SDC-4 and Id-1. It can be hypothesized that the mechanism by which GPI 15427 exerts the inhibitory effect on angiogenesis (10), might be ascribed to a reduced PARP-mediated regulation of the activity of certain transcription factors that control endothelial functions. In this context, inhibition of Oct-1 and CREB/ATF family of transcription factors might be crucial in the down-modulation of molecules involved in endothelial cell migration, adhesion, proliferation or differentiation during the angiogenic process.
